Background: CLARINET is a landmark study that established the antitumour activity of LAN in patients with metastatic intestinal or pancreatic NETs. Here, we report final long-term safety data from the recently completed OLE. Table. The most common class of AEs on LAN:LAN across both studies was GI events (any AE, 81%; any treatment-related AE [TRAE], 43% ); among these, the most frequent were diarrhoea (any AE, 40%; any TRAE, 31%) and abdominal pain (any AE, 38%; any TRAE, 17%). On PBO:LAN in the OLE study, GI events (any AE/any TRAE) occurred in 66%/36%; with diarrhoea in 32%/26% and abdominal pain in 21%/2%. Only five patients withdrew due to AEs, of which only one was treatment-related. No new safety concerns were identified.
The most common class of AEs on LAN:LAN across both studies was GI events (any AE, 81%; any treatment-related AE [TRAE], 43% ); among these, the most frequent were diarrhoea (any AE, 40%; any TRAE, 31%) and abdominal pain (any AE, 38%; any TRAE, 17%). On PBO:LAN in the OLE study, GI events (any AE/any TRAE) occurred in 66%/36%; with diarrhoea in 32%/26% and abdominal pain in 21%/2%. Only five patients withdrew due to AEs, of which only one was treatment-related. No new safety concerns were identified. Any AE, n (%) 39 (93) 34 (81) 40 (95) 44 (94) 42 (89) Severe 10 (24) 12 (29) 18 (43) 13 (28) 13 (28) Moderate 19 (45) 16 (38) 17 (40) 23 (49) 22 (47) Mild 9 (21) 6 (14) 4 (10) 8 (17) 7 (15) Treatment-related 23 (55) 17 (40) 27 (64) 12 (26) 22 (47) Serious AEs, n (%)
9 (21) 11 (26) 17 (40) 12 (26) 14 (30) Treatment-related 1 (2) 2 (5) 3 (7) 1 (2) 2 (4) Withdrawals due to AEs, n (%)
NA, not applicable (no patients withdrawn from core study were entered into OLE study).
Conclusions: LAN 120 mg treatment, over a period of up to >4 years, showed favourable safety/tolerability in patients with metastatic intestinal and pancreatic NETs. This supports the positive longer-term benefit-risk profile of LAN as an antitumour treatment, which is consistent with previous experience from shorter-term trials. 
